The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recently explored how patient-provided information could be utilized to bolster real-world evidence.
The session during the society’s recent meeting in New Orleans featured:
- Cristina Masseria, Pfizer;
- Elisabeth Oehrlein, National Health Council;
- Chris Pashos, AbbVie; and
- Richard Willke, ISPOR.
According to a press release, ISPOR and the International Society for Pharmacoepidemiology (ISPE) formed an RWE task force and discussed the issue during a summit in 2017.
“Employing patient insights into the disease and treatment situation is invaluable for designing a meaningful, impactful real-world study,” Willke said during the session.
To read the full press release, click here.
